A cough is a protective reflex designed to clear the respiratory tract of foreign particles, mucus, and irritants. The physiological mechanism involves a complex arc: irritant receptors in the pharynx, larynx, trachea, or large bronchi detect a stimulus. Afferent nerve fibers, primarily through the vagus nerve, transmit these impulses to the cough center located in the medulla oblongata of the brainstem. The medulla then coordinates efferent signals traveling via the vagus, phrenic, and spinal motor nerves to the respiratory muscles, glottis, and abdominal wall, resulting in a sudden, forceful expulsion of air.
Antitussive agents are pharmacological substances designed to suppress this cough reflex. They are generally indicated only when a cough is non-productive, dry, and exhausting to the patient, as suppressing a productive cough can lead to retained pulmonary secretions and atelectasis.
Antitussives are broadly categorized into two main groups based on their chemical structure and central nervous system action: opioid and non-opioid agents.
The pharmacodynamics of antitussives depend entirely on whether the drug is central or peripheral in action. Central antitussives bind to specific opioid receptors in the solitary tract of the medulla, dampening the neuronal firing that triggers the motor response of a cough. Dextromethorphan exerts an NMDA receptor antagonism effect alongside its sigma receptor activity, which contributes to its cough-suppressant properties.
Peripheral antitussives, such as benzonatate, work by binding to voltage-gated sodium channels in the sensory nerves of the lungs and pleura. By stabilizing these membranes, they prevent the transmission of afferent impulses from stretched pulmonary receptors to the central nervous system. Patients must be instructed to swallow benzonatate capsules whole; chewing them can numb the oral mucosa and pharynx, creating a severe choking hazard.
The primary clinical indication for antitussive therapy is the management of disruptive, dry, hacking coughs that interfere with sleep, rest, or daily functioning. They are frequently used in viral upper respiratory tract infections, acute bronchitis, and post-viral tussive syndromes.
Antitussives are not recommended for chronic productive coughs associated with conditions like chronic bronchitis or bronchiectasis, where clearing mucus is vital to patient survival. In palliative care, opioid antitussives are sometimes utilized to ease terminal dyspnea and persistent coughing associated with advanced lung malignancies.
Adverse reactions vary between central and peripheral agents. Opioid antitussives frequently cause drowsiness, dizziness, constipation, nausea, and respiratory depression. Non-opioids like dextromethorphan are generally well tolerated at therapeutic doses, but high recreational doses can cause dissociation, hallucinations, and CNS toxicity.
Contraindications include known hypersensitivity, chronic productive coughs, and impaired respiratory reserve. A critical drug interaction occurs between dextromethorphan and Monoamine Oxidase Inhibitors (MAOIs), which can precipitate life-threatening serotonin syndrome characterized by hyperthermia, hypertension, and tremors.
Comprehensive nursing care requires evaluating the nature of the cough, lung sounds, sputum production, and vital signs before administering any antitussive. The nurse must verify that the patient does not have a productive cough that requires clearance.
Patient education focuses on safe administration practices, hydration, and recognizing warning signs. Patients should increase fluid intake to help liquefy respiratory secretions. Nurses must instruct patients to avoid hazardous activities like driving if the medication causes drowsiness, and to report a cough that persists for more than a week, worsens, or is accompanied by high fever or chest pain.